Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SyB C-1101 in Patients With Myelodysplastic Syndrome
NCT03495167Phase 1Completed
- Sponsor
- SymBio Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by SymBio Pharmaceuticals. Primary endpoint: Dose-Limiting Toxicity up to 2 years. Started Oct 2017; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03495167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03495167.